Skip to main content

Table 2 Results of Cost-effectiveness Analysis

From: Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis

Strategy

Cost

Incremental Cost

Un adjusted Life-years

Incremental LYs

QALYs

Incremental QALYs

ICER ($/QALY)

SSA

$606,397

$170,455

4.41

0.62a

2.90

0.44

$388,966

Delay SSA

$435,942

–

3.78

–

2.46

–

–

  1. aNumbers do not sum because of rounding
  2. SSA somatostatin analogues; LY life years; QALYs quality-adjusted life years; ICER incremental cost-effectiveness ratio